Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
4D Path (BAX) announced the first close of a strategic financing to accelerate development of treatment‑predictive biomarkers for solid tumors and partnerships with biopharma. The company appointed Katherine Vega Stultz as Board Chair and added Robert J. Hombach to the board to strengthen clinical, commercial and financial leadership.
The release highlights pan‑cancer potential and prior clinical relevance across breast, ovarian, colorectal and skin cancers, and frames the board changes plus financing as catalysts for accelerated growth and partnership activity.
Baxter (NYSE: BAX) reported continuing-operations sales of $2.7B for Q1 2026, up 3% reported and down 1% organic. U.S. sales were $1.44B (down 4%), international sales $1.27B (up 12% reported). GAAP loss per share was ($0.03); adjusted EPS was $0.36 (down 35%). Company reiterated full-year 2026 outlook: reported sales flat to 1%, organic approximately flat, adjusted EPS $1.85–$2.05.
Baxter (NYSE:BAX) is showcasing recent surgical innovations at the AORN Global Surgical Conference & Expo, April 11-14, 2026 in New Orleans. Featured products include the AAT XR spine surgical table and the Dynamo Series smart stretcher, plus Baxter’s Advanced Surgery hemostatic and sealing portfolio.
The AAT XR supports 180-degree rotation, up to 650 lb capacity, a lithium-ion battery, and U.S. availability expected early in H2 2026; the Dynamo Series is currently available in the U.S.
Baxter (NYSE:BAX) will host a conference call to review first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. CT. Investors may pre-register to receive call details and the event will be webcast on Baxter’s website.
The call will be recorded and is copyrighted; recording or rebroadcast requires Baxter permission.
Baxter (NYSE:BAX) on March 30, 2026 launched the IV Verify Line Labeling System, an automated bedside solution from a distribution agreement with Vigilant Software to standardize IV line labeling and support safer medication administration.
The system prints color-coded, ink-free three-part labels after barcode scanning; studies cited include a 10-hospital ICU review (60% noncompliance) and reported clinician time savings of one to two minutes per IV setup. One health system reported improved labeling compliance and a meaningful reduction in CLABSI when IV Verify was part of a CLABSI bundle. The product is available now in the U.S.
Baxter (NYSE:BAX) will hold its 2026 Annual Meeting of Stockholders virtually on May 5, 2026 at 9:00 a.m. Central Time, with online access beginning at 8:45 a.m. Central Time. Stockholders cannot attend in person and are encouraged to vote in advance by methods in the proxy materials.
Record holders may join at www.virtualshareholdermeeting.com/BAX2026 using their 16-digit control number; guests may listen only. Questions may be submitted in advance April 21–May 4 or live during the meeting, and unanswered meeting questions will be posted afterward.
Pet Partners and the Baxter Foundation (NYSE:BAX) launched a two-year pilot to expand therapy animal visits in U.S. healthcare settings, targeting 100,000 patients and healthcare workers. The pilot covers Northern California, Upstate New York and Greater Chicago and funds training, safety updates, research, volunteer recruitment and employee engagement.
The initiative aims to reduce stress and improve resilience for patients and care teams by scaling evidence-based animal-assisted interventions.
Baxter (NYSE:BAX) announced a CFO transition on March 16, 2026: Joel Grade will depart and remain an advisor through April 30, 2026.
Anita Zielinski is named interim CFO effective immediately while continuing as SVP, chief accounting officer and controller; the company reiterated its full-year 2026 outlook.
Baxter (NYSE:BAX) reported fourth-quarter 2025 continuing-operations sales of $2.97 billion (up 8% reported, 3% operational) and a U.S. GAAP net loss from continuing operations of ($1,035) million or ($2.01) per diluted share.
Adjusted diluted EPS from continuing operations was $0.44, down 24% year-over-year. The quarter included a $485 million goodwill impairment and a $330 million valuation allowance on U.S. deferred tax assets. Full-year 2026 adjusted EPS guidance is $1.85–$2.05 with sales expected to be flat to +1%.
Baxter (NYSE:BAX) will host a conference call to discuss fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. Investors can pre-register at the provided registration link to receive call details and access a live webcast via the company's website. The call will be recorded by Baxter and is copyrighted; recording or rebroadcasting by third parties is prohibited without permission.